Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 2
Submit an article Journal homepage
360
Views
5
CrossRef citations to date
0
Altmetric
Original Articles

Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study

Mansi Bhurania Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;b Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia;c Faculty of Medicine, Nursing, and Health Sciences, Monash University, Melbourne, VIC, Australia
,
Lorenz Admojoa Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;b Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia
,
Carrie Van Der Weydena Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;b Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, AustraliaCorrespondence[email protected]
,
Robert Twiggera Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;b Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia
,
Ali Bazargand St Vincent’s Health, Melbourne, VIC, AustraliaORCID Iconhttps://orcid.org/0000-0001-6566-6215
ORCID Icon,
Hang Quachd St Vincent’s Health, Melbourne, VIC, AustraliaORCID Iconhttps://orcid.org/0000-0002-4796-3352
ORCID Icon,
Allan Zimete Epworth Healthcare, Melbourne, VIC, Australia
,
Luke Coylef Royal North Shore Hospital, Sydney, NSW, Australia
,
Julian Lindsayf Royal North Shore Hospital, Sydney, NSW, Australia
,
Dejan Radeskig Sir Charles Gairdner Hospital, Nedlands, WA, Australia
,
Eliza Hawkesh Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, VIC, Australia
,
Glen Kennedyi Mater Cancer Care Centre, Brisbane, QLD, Australia
,
Ian Irvingj Icon Cancer Care, Brisbane, QLD, Australia
,
Naadir Guttaj Icon Cancer Care, Brisbane, QLD, Australia
,
Judith Trotmank Concord Hospital, Sydney, NSW, Australia
,
James Yeungk Concord Hospital, Sydney, NSW, Australia;l Royal Prince Alfred Hospital, Sydney, NSW, Australia
,
Lindsay Dunlopm Southern Highland Private Hospital, Liverpool, NSW, Australia
,
Minh Hual Royal Prince Alfred Hospital, Sydney, NSW, Australia
,
Pratyush Girin Royal Adelaide Hospital, Adelaide, SA, Australia
,
Sam Yueno Calvary Mater, Newcastle, NSW, Australia
,
Shyam Panickerp Hills Specialist Group, Bella Vista, NSW, Australia
,
Susan Moretonq Dubbo Base Hospital, Dubbo, NSW, Australia
,
Liane Khool Royal Prince Alfred Hospital, Sydney, NSW, Australia
,
Ashleigh Scottr Royal Brisbane and Women’s Hospital, Herston, QLD, Australia;s Sir Peter MacCallum Department of Surgical Oncology, Parkville, VIC, Australia
,
David Kippt Barwon Health Cancer Services, Geelong, VIC, Australia
,
Andrew McQuillanu Hollywood Medical Centre, Nedlands, WA, Australia
,
Chris McCormacka Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;s Sir Peter MacCallum Department of Surgical Oncology, Parkville, VIC, Australia
,
Michael Dickinsona Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;b Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia
&
Henry Miles Princea Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;b Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia;c Faculty of Medicine, Nursing, and Health Sciences, Monash University, Melbourne, VIC, Australia;e Epworth Healthcare, Melbourne, VIC, Australia
 show all
Pages 330-336 | Received 02 Oct 2019, Accepted 07 Sep 2020, Published online: 07 Oct 2020

References

  • Bellei M, Nabhan C, Pesce E, et al. The value and relevance of the T cell lymphoma registries and international collaborations: The Case of COMPLETE and the T-Cell Project. Curr Hematol Malig Rep. 2015;10:445–448.
  • Swerdlow S, Campo E, Pileri S, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390.
  • Moskowitz A, Lunning M, Horwitz S. How I treat the peripheral T-cell lymphomas. Blood. 2014;123:2636–2644.
  • AbouYabis A, Shenoy P, Sinha R, et al. A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol. 2011;2011:623914–623924.
  • Horwitz S, O'Connor O, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393:229–240.
  • Mahadevan D, Unger J, Spier C, et al. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma. Cancer. 2013;119:371–379.
  • Wilhelm M, Smetak M, Reimer P, et al. First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation. Blood Cancer J. 2016;6:e452–e452.
  • Van Leeuwen M, Turner J, Joske D, et al. Lymphoid neoplasm incidence by WHO subtype in Australia 1982-2006. Int J Cancer. 2014;135:2146–2156.
  • Zinzani P, Bonthapally V, Huebner D, et al. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas. Crit Rev Oncol Hematol. 2016;99:214–227.
  • Whittaker S, Hoppe R, Prince H. How I treat mycosis fungoides and Sezary syndrome. Blood. 2016;127:3142–3153.
  • Hughes C, Khot A, McCormack C, et al. Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome: a comparative study of systemic therapy. Blood. 2015;125:71–81.
  • Marchi E, Paoluzzi L, Scotto L, et al. Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies. Clin Cancer Res. 2010;16:3648–3658.
  • O'Connor O, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the Pivotal PROPEL Study. J Clin Oncol. 2011;29:1182–1189.
  • Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31:1970–1976.
  • Malik S, Liu K, Qiang X, et al. Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration Drug Approval Summary. Clin Cancer Res. 2010;16:4921–4927.
  • Shustov A, Pro B, Gisselbrecht C, et al. Pralatrexate is effective as second-line treatment following cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) failure in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Blood. 2010;116:4882–4882.
  • Maruyama D, Nagai H, Maeda Y, et al. Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma. Cancer Sci. 2017;108:2061–2068.
  • Horwitz S, Kim Y, Foss F, et al. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2012;119:4115–4122.
  • O’Connor O, Amengual J, Colbourn D, et al. Pralatrexate: a comprehensive update on pharmacology, clinical activity and strategies to optimize use. Leuk Lymphoma. 2017;58:2548–2557.
  • Zinzani P, Pellegrini C, Cerciello G, et al. Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program. Leuk Lymphoma. 2016;57:2370–2374.
  • Pro B, Horwitz S, Prince H, et al. Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma. Hematol Oncol. 2017;35:914–917.
  • Ghione P, Ozkaya N, Faruque P, et al. Romidepsin activity in T follicular helper (TFH)-phenotype PTCL versus non TFH treated on the same clinical trials. J Clin Oncol. 2018;36:7509–7509.
  • Zhu J, Yeoh E, Maeda Y, et al. Efficacy and safety of single-agent pralatrexate for treatment of angioimmunoblastic T-cell lymphoma after failure of first line therapy: a pooled analysis. Leuk Lymphoma. 2020;61:2145–2148.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.